Navigation Links
Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Date:3/10/2008

chnology company specializing in the discovery, development and manufacturing of therapeutic antibodies. At XOMA, he directed preclinical research and coordinated discovery and development activities in a number of therapeutic areas, including infectious diseases, inflammatory disorders and cancer.

Dr. Gundel also served as Vice President, Pharmacology and Preclinical Research at Chiron Corporation, where he supervised efforts to identify and characterize novel therapeutics for inflammatory diseases. Earlier, Dr. Gundel worked at Bayer Corporation where he held various positions within the Biotechnology Unit including Director of Pharmacology. He began his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc., where he supervised efforts to identify and characterize novel therapeutics for inflammatory diseases.

Dr. Gundel earned his M.B.A. from Saint Mary's College, and his Ph.D. in physiology from New York Medical College. He has participated in over 45 national and international scientific meetings as an invited speaker and/or session chairperson. He has published more than 60 articles in peer reviewed journals and book chapters, served on the editorial board of several journals and is a co-inventor on several issued U.S. patents.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious diseases. In March of 2007, the company's anthrax antibody therapeutic, Anthim, was selected to R&D Directions' list of "100 Great Investigational Drugs." Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
4. ExonHit Therapeutics - 2007 Financial Results
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
9. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced that it will host an investment community conference ... December 9, to discuss results of the Company,s Phase ...
... 6, 2010 Viruses have a bad rep—and rightly ... precisely replicate itself makes it a destructive scourge to ... researchers at the University of Maryland,s A. James Clark ... Resources, brought together by Professor Reza Ghodssi, is turning ...
... Todd Hutchings has assumed leadership of Egon Zehnder ... who led the practice, will continue at the firm ... executives. In his new role, Mr. Hutchings ... with boards and providing the full array of functional ...
Cached Biology Technology:Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time 2Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2
(Date:4/16/2014)... of Nicaragua,s legal, artisanal green sea turtle fishery has ... of turtles in what may have become an unsustainable ... Society and University of Florida. , During the research ... turtles were killed between 1991 and 2011, with catch ...
(Date:4/16/2014)... Florida State University researchers have identified a new ... bone density and muscle mass with obesity. , "It ... were the better your bones would be because the ... Hazel Stiebeling Professor of Nutrition at Florida State. "But, ...
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3Researchers: Obesity can amplify bone and muscle loss 2Researchers track down cause of eye mobility disorder 2
... as a model to study embryo formation, scientists report ... of a protein called Bicoid is vital to normal ... by the journal Dec. 19, the study shows how ... identified protein the researchers named Fates-shifted (Fsd). Without the ...
... Society has announced the winners of its second annual ... Annual Meeting at the Baltimore Convention Center in Baltimore, ... Professional Opportunities for Women, has initiated these travel fellowships ... their participation at the Meeting. The recipients of ...
... The prolonged, extensive emission of greenhouse gases over ... ocean life, according to a study by UC Merced ... emissions exacerbated by the burning of fossil fuels ... more acidic, and Beman,s study shows that the increased ...
Cached Biology News:Fruit fly study digs deeper into poorly understood details of forming embryos 2Biophysical Society announces winners of 2011 CPOW Travel Awards 2Rising greenhouse gases profoundly impact microscopic marine life 2
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: